GSK resolves FCPA case with US$20 million SEC settlement and DOJ declination

GlaxoSmithKline, one of the larger companies to be ensnared in a seven-year-old foreign bribery sweep of the pharmaceutical industry by US authorities, announced today that it had resolved FCPA allegations at its China-based subsidiaries by paying a US$20 million civil fine to the Securities and Exchange Commission.

Get unlimited access to all Global Investigations Review content